On the HCPLive Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.
March 7th 2024
On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.
February 26th 2024
February 7th 2024
Earn CME Credits While Advancing Your Expertise in Internal Medicine
April 18-19, 2024
Register Now!
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
Advances In™: The Potential Role of Ultra-Long-Acting Basal Insulin Therapies in Type 2 Diabetes
View More
6th Annual Advanced Practice Collaborative
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Cases and Conversations™: Guideline Recommendations for the Use of Basal Insulin Therapy in Type 2 Diabetes
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
Clinical Consultations™: Optimal Approaches to Recognizing and Treating ANCA-Associated Vasculitis
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
From NAFLD to MASLD: 2023 Brings New Liver Disease Nomenclature
December 13th 2023Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.
Diabetes Dialogue: SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
November 11th 2023In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD
November 11th 2023Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
Kidney Week 2023: Evolving Recognition of Cardiovascular, Kidney, and Metabolic Disease
November 7th 2023Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.
Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data
September 25th 2023A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.
Diabetes Dialogue: STEP-HFpEF Reaction
August 27th 2023Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.
Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity
August 25th 2023Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.
Study Estimates More than 90 Million US Adults Could Benefit from Semaglutide 2.4 mg
August 21st 2023Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.
Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs
August 15th 2023In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.
GLP-1 RAs and the Evolving Role of Cardiologists in Obesity Management, with Michael Blaha, MD
August 8th 2023In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.
SELECT Trial Shows Semaglutide 2.4 mg Could Reduce Cardiovascular Risk
August 8th 2023Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.